Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti ‐tumour necrosis factor

ConclusionsVedolizumab/anti‐TNF co‐exposure did not generate new safety signals during 14‐weeks induction, nor did it reduce efficacy or alter vedolizumab pharmacokinetics. These observations may aid the design of future co‐biologics trials and also suggest that a deliberate waiting‐interval between anti‐TNF cessation and subsequent vedolizumab initiation may not be warranted.

Source: Alimentary Pharmacology and Therapeutics - February 15, 2018 Category: Drugs & Pharmacology Authors: S. Ben ‐Horin, B. Ungar, U. Kopylov, A. Lahat, M. Yavzori, E. Fudim, O. Picard, Y. Peled, R. Eliakim, E. Del Tedesco, S. Paul, X. Roblin Tags: ORIGINAL ARTICLE Source Type: research